At a Glance
OrbiMed was founded in 1989 and has grown to become one of the world's largest healthcare-dedicated investment firms, managing over $18 billion across public and private strategies. The firm was established by Samuel Isaly and has built an unparalleled reputation in healthcare investing, spanning biotechnology, pharmaceuticals, medical devices, and digital health. OrbiMed operates across the entire healthcare investment spectrum, from early-stage venture investments to public market strategies, giving them unique insights into healthcare trends and opportunities. The firm has been involved in some of the most significant healthcare investments and IPOs, including early investments in companies like Moderna and 10x Genomics. What distinguishes OrbiMed is its deep scientific expertise, with a team that includes former pharmaceutical executives, physicians, and scientists who can evaluate complex healthcare technologies. The firm's global presence, with offices in New York, San Francisco, Mumbai, and other locations, allows them to identify and support healthcare innovation worldwide.
“Dedicated exclusively to healthcare investing, bringing deep scientific and clinical expertise to biotech, pharma, and medical device companies.”
OrbiMed primarily invests at the Series A, Series B+ stages. This means they focus on companies that are scaling their go-to-market after proving product-market fit.
OrbiMed is headquartered in New York, NY. Many of their portfolio companies are also based in this region, though they invest across geographies.
OrbiMed focuses on investments in Biotech, Digital Health. Their portfolio reflects deep expertise and networks within these sectors.
OrbiMed's typical investment check size ranges from $5M to $200M. Actual amounts may vary based on the stage, sector, and specific opportunity.
OrbiMed manages approximately $18B in assets under management (AUM) across their funds.